Last reviewed · How we verify
Dermatomyositis
Approved treatments
- Aminobenzoate Potassium
Aminobenzoate Potassium works by inhibiting the enzyme carbonic anhydrase 2, which plays a crucial role in maintaining the pH balance in cells. - Benzeneformic Acid
- Imuran · Legacy Pharma
- orthocaine
Pipeline
- Tofacitinib XR · Pfizer Inc. — Phase 1
Competitive intelligence
For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:
- Dermatomyositis patent landscape — cliff calendar, originator estates, attackable patents
- Dermatomyositis treatment landscape brief
- Dermatomyositis treatment updates RSS
Frequently asked questions about Dermatomyositis
What drugs treat Dermatomyositis?
Tracked treatments include Aminobenzoate Potassium, Benzeneformic Acid, Imuran, orthocaine.
What is the treatment for Dermatomyositis?
Standard treatment for Dermatomyositis includes Aminobenzoate Potassium, Benzeneformic Acid, Imuran, orthocaine. See the treatment landscape page for first-line, second-line and salvage options.
What new drugs are in development for Dermatomyositis?
1 pipeline drugs tracked. Top candidates: Tofacitinib XR.
Related
- Treatment landscape: Dermatomyositis patent cliff · Dermatomyositis CI report
- Treatment: Aminobenzoate Potassium
- Treatment: Benzeneformic Acid
- Treatment: Imuran · Legacy Pharma
- Treatment: orthocaine
- All diseases: Browse the disease index · Disease landscape hub
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing